| Breakdown | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 89.83M | 87.60M | 73.28M | 66.18M | 62.19M |
| Gross Profit | 65.28M | 63.08M | 57.24M | 51.13M | 45.05M |
| EBITDA | 24.94M | 22.04M | 20.31M | 18.61M | 18.54M |
| Net Income | 6.16M | 5.26M | 5.58M | 5.04M | 6.03M |
Balance Sheet | |||||
| Total Assets | 154.36M | 146.48M | 151.47M | 130.03M | 133.57M |
| Cash, Cash Equivalents and Short-Term Investments | 8.27M | 11.66M | 14.82M | 13.86M | 18.28M |
| Total Debt | 24.36M | 23.51M | 30.68M | 22.34M | 28.87M |
| Total Liabilities | 71.48M | 68.20M | 78.20M | 62.61M | 72.76M |
| Stockholders Equity | 82.87M | 78.28M | 73.28M | 67.42M | 60.81M |
Cash Flow | |||||
| Free Cash Flow | 17.86M | 12.44M | 10.08M | 8.09M | 10.81M |
| Operating Cash Flow | 18.54M | 21.11M | 18.60M | 15.65M | 16.55M |
| Investing Cash Flow | -17.02M | -11.00M | -22.55M | -9.84M | -5.54M |
| Financing Cash Flow | -5.19M | -13.63M | 4.71M | -10.62M | -23.08M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | £441.96M | 52.48 | 1.56% | 1.73% | -0.18% | 11.49% | |
70 Outperform | £152.12M | 18.83 | 15.34% | 1.71% | 3.48% | 318.89% | |
68 Neutral | £202.88M | 48.57 | 9.59% | 0.80% | 22.80% | -32.13% | |
65 Neutral | £321.93M | 52.30 | 8.06% | 1.04% | 10.93% | 12.30% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
58 Neutral | £80.44M | 2,400.00 | 0.15% | ― | 5.35% | -97.78% | |
46 Neutral | £95.95M | -66.01 | -3.40% | ― | -14.23% | 97.27% |
Idox reported its seventh consecutive year of revenue and adjusted EBITDA growth for FY25, with revenue up 3% to £89.8m and adjusted EBITDA rising 4% to £27.0m, as recurring revenue grew 10% and a record £108m order intake strengthened visibility into FY26 despite weaker non‑recurring election‑related sales. The group expanded its health and social care footprint with the Plianz acquisition and Ayup asset purchase and continued to invest in its India Global Capability Centre, while net debt rose due to M&A and the board withheld an FY25 dividend amid an ongoing recommended cash takeover offer from Long Path Partners’ vehicle Frankel UK Bidco, which is seeking majority control via a contractual offer running into March 2026.
The most recent analyst rating on (GB:IDOX) stock is a Buy with a £78.00 price target. To see the full list of analyst forecasts on Idox plc stock, see the GB:IDOX Stock Forecast page.
Idox plc has announced an adjournment of its Court Meeting and General Meeting regarding the recommended cash acquisition by Frankel UK Bidco Limited, a company indirectly owned by Long Path investment funds. The adjournment, intended to allow more time for discussions with shareholders, reschedules the meetings to January 6, 2025, reflecting the company’s commitment to ensuring shareholder engagement and consideration of the acquisition terms.
The most recent analyst rating on (GB:IDOX) stock is a Hold with a £76.00 price target. To see the full list of analyst forecasts on Idox plc stock, see the GB:IDOX Stock Forecast page.
Idox plc, a company involved in providing software solutions, has announced a recommended cash acquisition by Frankel UK Bidco Limited, which is indirectly owned by Long Path Co-Investment Fund and its affiliates. The acquisition will be conducted through a court-sanctioned scheme of arrangement, with Idox shareholders being advised to vote in favor of the scheme. The Court Meeting and General Meeting, initially scheduled for December 15, 2025, have been adjourned to January 6, 2026, to allow more time for discussions with shareholders. The Idox directors unanimously recommend the acquisition terms, considering them fair and reasonable, and emphasize the importance of shareholder participation in the voting process.
The most recent analyst rating on (GB:IDOX) stock is a Hold with a £76.00 price target. To see the full list of analyst forecasts on Idox plc stock, see the GB:IDOX Stock Forecast page.